BIOTEC leads Thailand’s leapfrog towards self-sufficiency

Tropika

If all goes well, the first malaria drug developed by Thai
researchers could reach human clinical trials at the beginning of next
year.

The drug, dubbed P218, is the product of research carried out by a
group at BIOTEC, a
research centre created by the Thai government to generate biotechnology
innovations.

Although several international partners, including Medicines for
Malaria Venture (MMV), Yale University, London School of Hygiene &
Tropical Medicine and Monash University in Australia, have been involved
along the way, it was BIOTEC that conducted the initial research that
has eventually allowed new drug candidates, such as P218, to be
developed.

See the rest of the story here

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s